Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROVENTION BIO, INC.

(PRVB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/14/2021 09/15/2021 09/16/2021 09/17/2021 09/20/2021 Date
6.22(c) 6.41(c) 6.45(c) 6.67(c) 6.395 Last
676 131 465 960 426 182 1 213 326 436 710 Volume
-7.58% +3.05% +0.62% +3.41% -4.12% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 3,80 M - -
Net income 2021 -135 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,16x
Yield 2021 -
Sales 2022 29,6 M - -
Net income 2022 -153 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,33x
Yield 2022 -
Capitalization 423 M 423 M -
Capi. / Sales 2021 111x
Capi. / Sales 2022 14,3x
Nbr of Employees 59
Free-Float 79,5%
More Financials
Company
Provention Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product... 
Sector
Biotechnology & Medical Research
Calendar
09/22 | 09:05amPresentation
More about the company
Ratings of Provention Bio, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about PROVENTION BIO, INC.
09/16PROVENTION BIO : to Present at the Oppenheimer Fall Healthcare Life Sciences and..
PR
09/13Provention Bio, Inc. Provides Update on the Potential Timing of Teplizumab At..
CI
08/06PROVENTION BIO : Oppenheimer Adjusts Provention Bio PT to $16 From $18, Maintain..
MT
08/05PROVENTION BIO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
AQ
08/05PROVENTION BIO, INC. : Results of Operations and Financial Condition, Financial ..
AQ
08/05PROVENTION BIO : Earnings Flash (PRVB) PROVENTION BIO Posts Q2 Loss $-0.46, vs. ..
MT
08/05PROVENTION BIO : Reports Second Quarter 2021 Financial Results and Provides Busi..
PR
08/05Provention Bio, Inc. Reports Earnings Results for the Second Quarter Ended Ju..
CI
07/29PROVENTION BIO : to Report Second Quarter 2021 Financial Results on August 5, 20..
PR
07/19PROVENTION BIO : Levi & Korsinsky, LLP
AQ
07/19PRVB FINAL DEADLINE : Bronstein, Gewirtz & Grossman, LLC Reminds Provention Bio,..
BU
07/18SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
PR
07/16FINAL DEADLINE : ROSEN, A RANKED AND LEADING FIRM, Encourages Provention Bio, In..
PR
07/16THE LAW OFFICES OF FRANK R. CRUZ : Reminds Investors of Looming Deadline in the ..
BU
07/15GLANCY PRONGAY & MURRAY LLP : Reminds Investors of Looming Deadline in the Class..
PR
More news
News in other languages on PROVENTION BIO, INC.

- No features available -

More news
Analyst Recommendations on PROVENTION BIO, INC.
More recommendations
Chart PROVENTION BIO, INC.
Duration : Period :
Provention Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROVENTION BIO, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 6,67 $
Average target price 15,64 $
Spread / Average Target 135%
EPS Revisions
Managers and Directors
Ashleigh W. Palmer Chief Executive Officer & Director
Andrew T. Drechsler Chief Financial Officer
Wayne F. Pisano Chairman
Francisco Leon Chief Scientific Officer
Eleanor Leni Ramos Chief Operating & Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PROVENTION BIO, INC.-60.63%423
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850